Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 6/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31726917 | 0.86 | PTGES (0.41) | CYP1A2CYP2D6CYP2C9CYP2C19RXFP1 | |
| SCHEMBL23037500 | 0.86 | PTGES (0.41) | CYP1A2CYP2D6CYP2C9CYP2C19RXFP1 | |
| SCHEMBL18449315 | 0.81 | TNF (0.50) | CYP1A2CYP2D6CYP2C9CYP2C19RXFP1 | |
| SCHEMBL20073053 | 0.79 | HTT (0.49) | CYP1A2CYP2D6CYP2C9CYP2C19RXFP1 | |
| SCHEMBL361308 | 0.79 | ALK (0.42) | RXFP1LMNAKDM4EMEN1KMT2A | |
| SCHEMBL25390691 | 0.79 | CYP1A2 (0.43) | CYP1A2CYP2D6CYP2C9CYP2C19RXFP1 | |
| SCHEMBL14899569 | 0.79 | TNF (0.51) | CYP1A2CYP2D6CYP2C9CYP2C19RXFP1 | |
| SCHEMBL28140826 | 0.76 | CYP1A2 (0.41) | CYP1A2CYP2D6CYP2C9CYP2C19RXFP1 | |
| SCHEMBL16730927 | 0.76 | CYP1A2 (0.44) | CYP1A2CYP2D6CYP2C9CYP2C19RXFP1 | |
| SCHEMBL27916309 | 0.76 | CYP1A2 (0.44) | CYP1A2CYP2D6CYP2C9CYP2C19RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246128-A1 | BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-08-12 | — | — | US | claimed |
| EP-3807248-A1 | BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF | Council of Scientific and Industrial Research (IN) | 2021-04-21 | — | — | EP | claimed |
| EP-4608808-A1 | SOMATOSTATIN RECEPTOR 2 AGONISTS AND USES THEREOF | Basecamp Bio Inc. (KY) | 2025-09-03 | — | — | EP | disclosed |
| US-12172991-B2 | Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2024-12-24 | — | — | US | disclosed |
| WO-2024089668-A1 | SOMATOSTATIN RECEPTOR 2 AGONISTS AND USES THEREOF | BASECAMP BIO INC. (KY) | 2024-05-02 | — | — | WO | disclosed |
| US-20210246128-A1 | BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-08-12 | — | — | US | disclosed |
| EP-3807248-A1 | BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF | Council of Scientific and Industrial Research (IN) | 2021-04-21 | — | — | EP | disclosed |
| EP-2995618-B1 | [1,2,4]TRIAZOL [4,3-A]PYRIDINE DERIVATE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN) | 2019-01-09 | — | — | EP | disclosed |
| EP-2995618-B1 | [1,2,4]TRIAZOL [4,3-A]PYRIDINE DERIVATE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN) | 2019-01-09 | — | — | EP | disclosed |
| CN-105859684-B | Fused ring compound and preparation method, application and intermediate compound thereof | 四川赛诺唯新生物技术有限公司 | 2017-03-22 | — | — | CN | disclosed |
| US-9512121-B2 | [1,2,4] triazol [4,3-A] pyridine derivative, preparation method therefor or medical application thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2016-12-06 | — | — | US | disclosed |
| US-20160122339-A1 | [1,2,4] TRIAZOL [4,3-A] PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2016-05-05 | — | — | US | disclosed |
| US-20160122339-A1 | [1,2,4] TRIAZOL [4,3-A] PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2016-05-05 | — | — | US | disclosed |
| EP-2995618-A1 | [1,2,4]TRIAZOL [4,3-A]PYRIDINE DERIVATE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF | Jiangsu Hansoh Pharmaceutical Co., Ltd. (CN) | 2016-03-16 | — | — | EP | disclosed |
| EP-2995618-A1 | [1,2,4]TRIAZOL [4,3-A]PYRIDINE DERIVATE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF | Jiangsu Hansoh Pharmaceutical Co., Ltd. (CN) | 2016-03-16 | — | — | EP | disclosed |
| EP-2593107-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2013-05-09 | — | — | US | disclosed |
| WO-2012009194-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122339-A1 | [1,2,4] TRIAZOL [4,3-A] PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF | MET, CYP4F11, WEE1 | CYP1A2 330/4885CYP2D6 210/4885CYP2C9 131/4885 |
| US-12172991-B2 | Bicycle topoisomerase i inhibiting compounds, process for preparation and use thereof | TOP1, TOP2A, TOP2B | CYP1A2 196/4885CYP2D6 533/4885CYP2C9 370/4885 |
| US-20130116231-A1 | TYROSINE KINASE INHIBITORS | ABL1, ERBB2, MET | CYP1A2 3600/4885CYP2D6 2960/4885CYP2C9 4478/4885 |
| US-20210246128-A1 | BICYCLE TOPOISOMERASE I INHIBITING COMPOUNDS, PROCESS FOR PREPARATION AND USE THEREOF | TOP1, TOP2A, TOP2B | CYP1A2 196/4885CYP2D6 533/4885CYP2C9 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.